Hutchison MediPharma Ltd (HMP), the R&D unit of Hutchison China MediTech Ltd, has secured a licensing agreement for an early-stage oncology compound with Eli Lilly and Company – its third deal for a molecule in its six-compound clinical portfolio. The deal was announced on 9 October.
